What's Happening?
New research from the University of Colorado Anschutz indicates that a CAR T-cell therapy, mivocabtagene autoleucel (miv-cel), offers significant and lasting improvements for individuals with stiff person syndrome (SPS). The phase 2 clinical trial, sponsored
by Kyverna Therapeutics and led by Dr. Amanda Piquet, director of the autoimmune neurology program at the CU Anschutz School of Medicine, found that patients experienced substantial gains in mobility and a reduction in overall disability for at least one year post-treatment. Specifically, one year after a single treatment, patients completed a 25-foot walking test in nearly half the time it took before treatment. Furthermore, two-thirds of patients who initially required walking aids were able to complete the test without assistance. The therapy also led to sustained reductions in muscle stiffness and sensitivity to stimuli. All 26 patients in the trial completed the one-year study, with 92% remaining free of ongoing immune-suppressing treatments.
Why It's Important?
This research is critically important as stiff person syndrome is a rare, progressive autoimmune neurological disease with no currently approved therapies. The disease causes debilitating muscle stiffness, painful spasms, and difficulty walking, often leading to patients requiring walking aids or wheelchairs and facing permanent disability. The miv-cel therapy, which modifies a patient's own immune cells to target disease-causing cells, represents a potential paradigm shift from managing symptoms to addressing the underlying autoimmune processes. If approved, it could be the first FDA-approved treatment specifically for SPS and the first CAR T-cell therapy approved for an autoimmune disease, offering a new avenue for long-term relief and improved quality of life for affected individuals.
What's Next?
The findings from this registrational clinical trial are a crucial step towards potential FDA approval for miv-cel. Kyverna Therapeutics, the developer of the CAR T-cell therapy, plans to complete its rolling Biologics License Application (BLA) submission in the fourth quarter of 2026. If the FDA grants approval, miv-cel could become available as a treatment option, potentially transforming the landscape for SPS patients. Further research will likely focus on long-term outcomes, broader patient populations, and exploring the therapy's applicability to other autoimmune conditions, given its novel approach to targeting underlying disease mechanisms.
Beyond the Headlines
The success of CAR T-cell therapy in treating stiff person syndrome could have profound implications beyond this specific condition. It highlights the potential of cell-based therapies to offer lasting improvements for autoimmune diseases by targeting the root cause rather than just managing symptoms. This approach could pave the way for similar therapies in other autoimmune disorders, potentially reducing the need for continuous immunosuppressive medications and their associated side effects. The ethical considerations surrounding gene modification and the cost-effectiveness of such advanced therapies will also be important discussions as these treatments become more prevalent in the medical landscape.
